Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone
deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine
the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this
drug combination.